The necessity and safety of using favipiravir in the treatment of adult patients with mild COVID-19


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To provide evidence for the necessity and safety of using favipiravir for the treatment of adult patients with non-severe forms of COVID-19. Subjects and methods. Of the 168 study participants, 163 received at least one dose of the test drug or the comparator: 108 patients received etiotropic therapy with favipiravir (experimental group), 55 were treated with umifenovir or hydroxychloroquine (comparison group). The endpoints of the study were time to clinical improvement according to the WHO Ordinal Scale of Clinical Improvement, time to viral elimination and presence or absence of adverse events (AEs), directly caused by the applied drugs, as well as AEs severity. Results. AEs were reported in both groups. A short-term increase in the level of hepatic transaminases was most often observed in overall population. In the experimental group, the most common AE was hyperuricemia, which is an expected reaction that is managed by medication discontinuing and causes no long-term consequences. At the same time, higher rate of virus elimination was recorded in the favipiravir group: in 71.4% of participants in the experimental group vs. 57.1% in the comparison group (on Day 3 and in 81.2% vs. 67.9% on Day 5, respectively. Clinical improvement occurred 4 days earlier in the experimental group (p = 0.005). Conclusion. The use of etiotropic therapy for the treatment of COVID-19 at its early stages and in case of non-severe forms of the disease is reasonable, necessary, and reduces the risk of complications. The choice of favipiravir as an initial treatment is based on the fact that its use resulted in earlier elimination of SARS-CoV-2 virus and much earlier onset of clinical improvement (by 4 days) according to the WHO Ordinal Scale of Clinical Improvement, when compared to umifenovir or hydroxychloroquine. Evaluation of the safety profile of favipiravir revealed no serious AEs associated with its use. However, when prescribing the drug, it should be remembered that favipiravir is contraindicated for pregnant women due to its teratogenic effects on the fetus. In addition, both men and women should apply the additional contraceptive methods during the period of drug use and for the following 3 months.

Full Text

Restricted Access

About the authors

Tatiana A. Ruzhentsova

Ventral Research Institute of Epidemiology Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Bein

Email: ruzhencova@gmail.com
MD, Head, Clinical Research Department; Рrofessor, Educational Center Moscow, Russia

Pavel V. Chuchliaev

Ventral Research Institute of Epidemiology Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Bein

Email: pafachka@gmail.com
Leading Specialist, Qinical Research Department Moscow, Russia

Daria A. Khavkina

Ventral Research Institute of Epidemiology Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Bein

Email: havkina@gmail.com
Leading Specialist, Qinical Research Department Moscow, Russia

Alexander A. Garbuzov

Ventral Research Institute of Epidemiology Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Bein

Email: os.vertebra@gmail.com
Methodist, Qinical Research Department Moscow, Russia

Maria V. Nikolskaya

LLC «Drug Technology»

Email: nikolskaia@drugsformulation.ru
Head, Department of Medical information Khimki, Russia

Viktoria A. Razzhivina

LLC «Drug Technology»

Email: var@drugsformulation.ru
Can. Biol. Sci., Head, Department of Clinical Research Khimki, Russia

Olga V. Filon

LLC «Drug Technology»

Email: filon@drugsformulation.ru
Medical Director Khimki, Russia

References

  1. Colson P., Rolain J.M., Lagier J.C., Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int. J. Antimicrob. Agents 2020; 55(4): 105932. doi: 10.1016/j.ijantimicag.2020. 105932
  2. Руженцова Т.А., Хавкина Д.А., Чухляев П.В., Мешкова Н.А., Гарбузов А. А. Стратегия рациональной терапии острых респираторных инфекций у пациентов с комор-бидной соматической патологией. Безопасность и риск фармакотерапии 2020: 2(8); 77-83. doi.org/10.30895/2312-7821-2020-8-2-77-83.
  3. Руженцова Т.А., Горелов А.В. Значение острых респираторных вирусных инфекций в развитии хронической патологии сердца у детей. Эпидемиол. и инфекц. бол. 2012; 17(3); 42-6. doi: 10.17816/EID40658
  4. Руженцова Т.А., Плоскирева А.А., Щербаков И.Т., Исаева Е.И., Бондарева А.В., Горелов А.В. Поражения миокарда при Коксаки А вирусной инфекции. Фундаментальные исследования 2015: 1(5); 1033-7.
  5. Gautret Ph., Gautret P., Lagier J.C., Parola P. et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents 2020: 105949. doi: 10.1016/j.ijantimicag.2020.105949
  6. Yin-Xiao Du, Xiao-Ping Chen, Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection, Clinical Pharmacology & Therapeutics. April 2, 2020. doi: 10.1002/cpt.1844
  7. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Временные методические рекомендации Минздрава России. Версия 6 (28.04.2020). https://attaches/000/050/122/original/28042020_МR_COVID-19_v6.pdf
  8. Руженцова Т.А., Чухляев П.В., Хавкина Д.А., Гарбузов А.А., Осешнюк Р.А., Солуянова Т.Н., Шестакова И.В., Вафин А.Ю., Дмитрикова Е.П., Мустафаев Д., Домостроева Т.Н., Отпущенникова М.В., Покровский К.А., Русанова М.Г., Быстрицкий Д.А., Маркова Т.Н., Каплун Е.А., Петина Д.В., Костина Н.Э., Лесина В.С., Щербак С.Г., Агафьина А.С., Брук Ю.Ф., Бронов О.Ю., Шульц Е.И., Красавина Э.Н., Самсонов М.Ю., Зинченко А.В., Никольская М.В., Разживина В.А., Филон О.В. 2020. Эффективность и безопасность применения фавипиравира при COVID-19 легкого и среднетяжелого течения: результаты рандомизированного исследования. COVID-19. preprints.microbe. ru. https://doi.org/10.21055/preprints-3111892
  9. Руженцова Т.А., Чухляев П.В., Хавкина Д.А., Гарбузов А.А., Плоскирева А.А., Осешнюк Р.А., Солуянова Т.Н., Шестакова И.В., Вафин А.Ю., Дмитрикова Е.П., Мустафаев Д.М., Домостроева Т.Н., Красавина Э.Н., Самсонов М.Ю., Никольская М.В., Разживина В.А., Филон О.В. Возможности этиотропной терапии коронавирусной инфекции, вызванной SARS-CoV-2, у амбулаторных пациентов. Медицинский оппонент 2020: (1); 48-58. http://proffopponent.ru/2020/08/05/vozmozhnosti-jetiotropnoj-terapii-koronavirusnoj-infekcii-vyzvannoj-sars-cov-2-u-ambulatornyh-pacientov/
  10. Mishima E., Anzai N., Miyazaki M., Abe T. Uric Acid Elevation by Favipiravir, an Antiviral Drug. Tohoku J. Exp. Med. 2020; 251: 87-90.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2020 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies